MicroRNA-33b is a Potential Non-Invasive Biomarker for Response to Atorvastatin Treatment in Chilean Subjects With Hypercholesterolemia: A Pilot Study

التفاصيل البيبلوغرافية
العنوان: MicroRNA-33b is a Potential Non-Invasive Biomarker for Response to Atorvastatin Treatment in Chilean Subjects With Hypercholesterolemia: A Pilot Study
المؤلفون: Ignacio Obreque, Carmen Gloria Ubilla, Kathleen Saavedra, Jeremy Angulo, Luis A. Salazar, Nicolás Saavedra, Yalena Prado, Tomás Zambrano, Isis Paez
المصدر: Frontiers in Pharmacology, Vol 12 (2021)
Frontiers in Pharmacology
بيانات النشر: Frontiers Media S.A., 2021.
سنة النشر: 2021
مصطلحات موضوعية: 0301 basic medicine, Oncology, medicine.medical_specialty, Atorvastatin, RM1-950, 030204 cardiovascular system & hematology, statins, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, microRNA, medicine, Pharmacology (medical), epidrugs, Original Research, Pharmacology, hypercholesterolemia, business.industry, Non invasive biomarkers, atorvastatin, Circulating MicroRNA, 030104 developmental biology, circulating microRNAs, Therapeutics. Pharmacology, business, medicine.drug
الوصف: Evidence accumulated so far indicates that circulating levels of microRNAs (miRNAs) are associated with several pathologies. Therefore, differential expression of extracellular miRNAs exhibits promising potential for screening and diagnosis purposes. We evaluated plasma miRNAs in response to the lipid-lowering drug atorvastatin in patients with hypercholesterolemia (HC) and controls. Methods: We selected miRNAs based on previous data reported by our group and also by employing bioinformatics tools to identify 10 miRNAs related to cholesterol metabolism and statin response genes. Following miRNA identification, we determined plasma levels of miRNA-17-5p, miRNA-30c-5p, miRNA-24-3p, miRNA-33a-5p, miRNA-33b-5p, miRNA-29a-3p, miRNA-29b-3p, miRNA-454-3p, miRNA-590-3p and miRNA-27a-3p in 20 HC patients before and after 1 month of 20 mg/day atorvastatin treatment, evaluating the same miRNA set in a group of 20 healthy subjects, and employing qRT-PCR to determine differential miRNAs expression. Results: HC individuals showed significant overexpression of miRNA-30c-5p and miRNA-29b-3p vs. NL (p = 0.0008 and p = 0.0001, respectively). Once cholesterol-lowering treatment was concluded, HC individuals showed a substantial increase of three extracellular miRNAs (miRNA-24-3p, miRNA-590, and miRNA-33b-5p), the latter elevated more than 37-fold (p = 0.0082). Conclusion: Data suggest that circulating miRNA-30c-5p and miRNA-29b-3p are associated with hypercholesterolemia. Also, atorvastatin induces a strong elevation of miRNA-33b-5p levels in HC individuals, which could indicate an important function that this miRNA may exert upon atorvastatin therapy. Additional studies are needed to clarify the role of this particular miRNA in statin treatment.
اللغة: English
تدمد: 1663-9812
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35efb9226ca0096f433a495a7ea319f3
https://www.frontiersin.org/articles/10.3389/fphar.2021.674252/full
حقوق: OPEN
رقم الأكسشن: edsair.doi.dedup.....35efb9226ca0096f433a495a7ea319f3
قاعدة البيانات: OpenAIRE